{"id":"W4243183853","doi":"10.1093/jnci/95.10.762","title":"RESPONSE: Re: Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy","year":2003,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Darbepoetin alfa; Medicine; Placebo; Lung cancer; Chemotherapy; Double blind; Internal medicine; Epoetin alfa; Oncology; Randomized controlled trial; Alternative medicine; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00785344,0.001830704,0.003109887,0.0007033515,0.001405071,0.002220582,0.002602101,0.0235947,0.03053963],"category_scores_gemma":[0.03013775,0.0006089368,0.003208858,0.0006148249,0.001051169,0.002082921,0.000898785,0.01397419,0.01654106],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005419176,"about_ca_system_score_gemma":0.002908903,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003556187,"about_ca_topic_score_gemma":0.004731391,"domain_scores_codex":[0.9961971,0.001634303,0.0005387644,0.0005439126,0.0007424817,0.0003434538],"domain_scores_gemma":[0.9899986,0.005041169,0.0009146698,0.000402028,0.002779252,0.0008642825],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003738247,0.00009506262,0.0004508164,0.001173641,0.0002076941,0.0001863077,0.00004494039,0.00009343604,0.0002592563,0.0005647546,0.9813395,0.01184619],"study_design_scores_gemma":[0.02522879,0.001648467,0.0052274,0.003798638,0.0007831408,0.0005899202,0.0003143509,0.001160181,0.001364801,0.004907276,0.9547445,0.0002326058],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.002871278,0.004703386,0.0004870635,0.8905402,0.08048855,0.002799424,0.007824867,0.0005411471,0.009744177],"genre_scores_gemma":[0.008306122,0.001797952,0.0007637716,0.9303873,0.03172274,0.001952286,0.00113515,0.0001472955,0.02378737],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.03053963,"threshold_uncertainty_score":0.1021652,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04248703538255227,"score_gpt":0.3834268269602154,"score_spread":0.3409397915776631,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}